NCT06196554 2024-01-09
Gastric Cancer Organoids in the Screening of Neoadjuvant Drugs
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Unknown
Clinical Trials
26 trialsNCT06197438 2024-01-09
Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer
Fujian Cancer Hospital
Phase 2 Unknown
NCT04714190 2023-12-21
A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression
RemeGen Co., Ltd.
Phase 3 Unknown
NCT05750290 2023-03-01
CKD-702 Plus Irinotecan in Gastric Cancer
National Cancer Center, Korea
Phase 2 Unknown
NCT05643677 2022-12-09
Fruquintinib Plus Irinotecan in the Treatment of Advanced Gastric Cancer
Fujian Medical University
Phase 2 Unknown
NCT04358354 2021-07-19
Triplet Combination of Cytotoxics as First-line Treatment for Metastatic Gastric Cancer
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3 Unknown
NCT04934618 2021-06-22
A Phase II Study of Carelizumab Combined With Irinotecan and Apatinib of Second-line Treatment for Advanced Gastric Cancer
Nanfang Hospital, Southern Medical University
Phase 2 Unknown
NCT04915807 2021-06-07
Real-world Data (RWD) of Ramucirumab Plus Paclitaxel
Hallym University Medical Center
Unknown
NCT04393584 2021-04-13
RusGCG-01
Blokhin's Russian Cancer Research Center
Phase 2/3 Unknown
NCT04442984 2021-04-13
IRIGA
Blokhin's Russian Cancer Research Center
Phase 2 Unknown
NCT04486651 2021-01-28
HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer
Taizhou Hanzhong biomedical co. LTD
Phase 3 Unknown
NCT04358341 2020-08-24
Pegliposomal Doxorubicin and 5-fluorouracil as Second Line Therapy for Metastatic Gastric Cancer
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2 Unknown
NCT01271582 2019-01-29
Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients
Asan Medical Center
Phase 4 Unknown
NCT03668418 2018-09-12
xenoZ
University of Pisa
Unknown
NCT03400592 2018-01-17
NIEGA
Peking University
Phase 2 Unknown
NCT03061058 2017-09-15
Individualized Intraperitoneal and System Chemotherapy Versus System Chemotherapy as First-line Chemotherapy for AGC
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 3 Unknown
NCT02662959 2016-01-26
Irinotecan as 3rd Line Therapy in Gastric Cancer
Fudan University
Phase 2 Unknown
NCT02401971 2015-03-30
ITAGC
Zhengzhou University
Phase 4 Unknown
NCT00005607 2013-12-19
Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Cancer of the Stomach or Esophagus
National Cancer Institute (NCI)
Phase 2 Unknown
NCT01964027 2013-10-17
SIEG
Anhui Medical University
Phase 2 Unknown
NCT00134095 2013-09-17
S-1 and Irinotecan in Treating Patients Who Are Undergoing Surgery for Locally Advanced Stomach Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT01224652 2010-10-20
Efficacy Study of Paclitaxel Versus Irinotecan in Patients With Recurrent or Metastatic Gastric Cancer Who Progress Following First-line Therapy
Korean Cancer Study Group
Phase 3 Unknown
NCT00343668 2010-05-26
S-1 and Irinotecan Combination Chemotherapy for Advanced Gastric Cancer
Korean Cancer Study Group
Phase 2 Unknown
NCT00509964 2007-08-01
Second-Line Irinotecan vs. ILF for AGC
Gachon University Gil Medical Center
Phase 2 Unknown
NCT00506207 2007-07-25
TIROX
National Cancer Center, Korea
Phase 1 Unknown
NCT00320294 2007-03-12
ILF With/Without Cisplatin for Advanced Gastric Cancer
Gachon University Gil Medical Center
Phase 2 Unknown